The World Health Organization recommended the RTS,S/AS01 malaria vaccine (brand name Mosquirix) for widespread use in children in October 2021, marking the first vaccine ever approved against a parasitic disease. After 30+ years of development by GlaxoSmithKline and PATH, the vaccine showed 30-40% efficacy against malaria in clinical trials across seven African countries—modest compared to typical vaccines, but life-saving in regions where malaria kills over 400,000 people annually, mostly children under five.
How It Works
RTS,S targets the Plasmodium falciparum parasite during its sporozoite stage (when mosquitoes inject it into the bloodstream, before it reaches the liver). The vaccine trains the immune system to recognize the parasite’s circumsporozoite protein. It requires four doses over 18 months and efficacy wanes over time, making it a partial tool alongside bed nets, insecticides, and antimalarial drugs—not a silver bullet.
Deployment Challenges
Pilot programs in Ghana, Kenya, and Malawi (2019-2023) vaccinated over 1 million children, demonstrating feasibility despite the complex four-dose schedule. However, 30-40% efficacy meant 60-70% of vaccinated children still got malaria, leading to questions about cost-effectiveness (each course costs ~$10-15). A second vaccine, R21/Matrix-M developed by Oxford, showed 75-80% efficacy in 2023 trials and received WHO prequalification, potentially offering a more effective option.
Significance
The approval validated decades of parasitic vaccine research (historically considered too difficult) and provided hope for vaccines against other neglected tropical diseases. Twitter saw celebration from global health advocates (#EndMalaria) mixed with frustration that richer diseases like COVID-19 got faster vaccine development. The modest efficacy sparked debates about “good enough” solutions for diseases afflicting poor populations versus holding out for highly effective vaccines.
Sources: WHO October 2021 recommendation, GlaxoSmithKline clinical trial data, Lancet malaria vaccine studies, PATH Malaria Vaccine Initiative reports